← Eichor
Study identifier: NCT05679024 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

Condition: Chronic Kidney Diseases · Atrial Fibrillation · Stroke  ·  Sponsor: Region Stockholm

PhasePhase 3
Planned participants1400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Objective: To study the efficacy and safety of apixaban as stroke prophylaxis in patients with chronic kidney disease (CKD) stage 5 and atrial fibrillation (AF) with or without dialysis treatment. The study hypothesis is that compared to no anticoagulation, apixaban reduces the incidence of ischemic stroke without causing an unacceptable increase in fatal or intracranial bleeding events. The secondary objectives are to evaluate the risk of all-cause mortality, cardiovascular events, and major bleeding in people with CKD stage 5 and AF treated with apixaban compared to standard of care without anticoagulation. Trial design: Pragmatic Prospective Open Label Randomized Controlled Clinical Trial, phase 3b over 12-72 months. Trial population: 1000-1400 patients at ≈50 sites in Sweden, Finland, Norway, Iceland and Poland Eligibility criteria: Adults ≥18 years with CKD stage 5 (ongoing treatment with any chronic dialysis treatment OR an estimated glomerular filtration rate (eGFR)\* \<20 ml/min/1.73 m2 at least twice 3 months apart of which at least one occasion is \<15 ml/min/1.73 m2 due to CKD during the last 12 months) and a diagnosis of chronic, paroxysmal, persistent, or permanent AF or atrial flutter (AFL) with CHA2DS2-VASc score ≥2 for men or ≥3 or more for women as an indication for oral anticoagulation. The exclusion criteria are AF or AFL due to reversible causes, rheumatic mitral stenosis or moderate-to-severe non-rheumatic mitral stenosis at the time of inclusion into…

This description comes directly from the study's public registry record.

Talk to the study team

Marie Evans, Ass Prof  ·  +46760520852  ·  marie.evans@regionstockholm.se

Caroline Moberg  ·  caroline.moberg@ucr.uu.se

Always discuss trial participation with your own doctor first.

Locations (34)

Helsingfors University hospitalHelsinki, FinlandRecruiting
Tampere hospitalTampere, FinlandRecruiting
Turku hospitalTurku, FinlandRecruiting
Landspitali, the National University hospital of IcelandReykjavik, IcelandRecruiting
Oslo AkershusOslo, NorwayRecruiting
Oslo Universitetssjukhus UllevålOslo, NorwayRecruiting
Stavanger hospitalStavanger, NorwayRecruiting
Tromsö hospitalTromsø, NorwayRecruiting
Vestfold hospitalTønsberg, NorwayActive Not Recruiting
Falun hospitalFalun, Dalarna County, SwedenRecruiting
Östersund hospitalÖstersund, Jämtland County, SwedenNot Yet Recruiting
Lasarettet i FalunFalun, Region Dalarna, SwedenRecruiting

+ 22 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05679024